αvβ6靶向177Lu-PRRT联合奥拉帕利提升胰腺癌疗效
该研究将αvβ6靶向肽受体放射性核素治疗药物[177Lu]Lu-DOTA-ABM-5G与PARP抑制剂奥拉帕利联合,在αvβ6阳性的胰腺Capan-1细胞及小鼠移植瘤模型中评估疗效。体外联合治疗显著降低细胞活力、增加sub-G1和G2/M期细胞比例及γ-H2AX焦点数;体内联合治疗延缓肿瘤生长并显著改善中位生存期,未见治疗相关不良事件。
要点
- αvβ6靶向PRRT联合奥拉帕利在胰腺癌模型中疗效优于单药治疗。
- 联合治疗显著改善荷瘤小鼠中位生存期且未观察到治疗相关不良事件。
- 联合方案值得进一步研究,以满足胰腺癌迫切的治疗需求。
核心结论
- αvβ6靶向PRRT联合PARP抑制较单药治疗增强了疗效。
研究设计与样本
- 体外采用αvβ6阳性胰腺Capan-1细胞评估联合治疗对细胞活力、凋亡、细胞周期阻滞及双链断裂形成的影响。
- 体内在Capan-1移植瘤小鼠中开展药代动力学与疗效研究。
主要发现
- [177Lu]Lu-DOTA-ABM-5G在体外被αvβ6阳性Capan-1细胞快速内化,在体内被Capan-1移植瘤摄取。
- 联合治疗显著降低细胞活力(水溶性四唑盐1法),显著增加sub-G1和G2/M期细胞百分比,并较单药产生最多的每细胞γ-H2AX焦点数。
- 体内联合治疗延缓肿瘤生长进展并较对照和单药治疗显著改善中位生存期,未观察到治疗相关不良事件。
临床怎么用
- 该联合策略为αvβ6阳性胰腺癌提供潜在治疗方向,但尚需进一步临床前及临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic ductal adenocarcinoma is one of the most lethal malignances worldwide, and there remains an urgent need for more effective and less toxic treatment strategies. Integrin αvβ6 is a cell-surface receptor that is overexpressed in several malignancies, including pancreatic ductal adenocarcinoma, and plays a key role in invasion and metastasis, making it a promising molecular target for the detection and treatment of many cancers. We investigated a molecularly targeted approach that exploits the overexpression of αvβ6 using peptide receptor radionuclide therapy (PRRT) in combination with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib. Methods: We combined the αvβ6-targeted PRRT agent [177Lu]Lu-DOTA-ABM-5G with olaparib, a PARP inhibitor. The combination therapy was evaluated in vitro in αvβ6-positive pancreatic Capan-1 cells by investigating its effect on cell viability, apoptosis induction, cell cycle arrest, and the formation of double-strand breaks. In vivo pharmacokinetic and therapeutic efficacy studies were performed in mice bearing Capan-1 xenograft tumors. Results: In vitro, the [177Lu]Lu-DOTA-ABM-5G was rapidly internalized by αvβ6-positive pancreatic Capan-1 cells; in vivo, it was taken up by Capan-1 xenograft tumors in mice. Combination treatment with [177Lu]Lu-DOTA-ABM-5G and olaparib significantly reduced cell viability (water-soluble tetrazolium salt 1 assay), significantly increased the percentage of cells in the sub-G1 and G2/M phases (cell cycle analysis), and resulted in the greatest number of γ-H2AX foci per cell compared with single-agent treatment. In vivo, the combination treatment delayed tumor growth progression and significantly improved median survival compared with the control and single-agent treatments, with no observed treatment-related adverse events. Conclusion: The combination of αvβ6-targeted PRRT and PARP inhibition enhanced therapeutic efficacy compared with single-agent treatment. These findings warrant further investigation, particularly given the urgent need for improved treatments for pancreatic cancer.
引用
- Ganguly T, Harris RE, Hausner SH, et al. Combining an αvβ6-Targeted 177Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer. J Nucl Med. 2026. PMID: 42463291. doi:10.2967/jnumed.125.271137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。